PDGFRB and neoplasm: A trend of decreased mOS was observed in relation to Cyclin D1 overexpression and normal expression, with mOS of 20.09 vs. 33.23; p = 0.056, while high PDGFRβ expression in the tumor stroma resulted in survival rates of 24.90 vs. 48.36 months; p = 0.068.